Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

FEB 27, 2019 Opens: 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Drug Discovery 2019



After a hugely successful inaugural year, LabRoots and the Drug Discovery planning committee are pleased to announce the 2nd Annual Drug Discovery Virtual Conference. LabRoots will host the online-only event February 27, 2019. The Drug Discovery planning committee has carefully planned and selected speakers that best represent the key challenges, opportunities, and issues in the current landscape.


The theme for this year's event is Fitting All The Pieces Together with the following tracks:
  • Novel Strategies for Drug Discovery
    • Next-generation in Silico technologies
    • Organ on a Chip/3D Bioprinting
    • Second Harmonic Generation
    • Aptamers
  • Effective Tools for Drug Development
    • Artificial Intelligence
    • Well designed in Vivo Studies
    • Combination therapies to overcome therapeutic resistance
  • Innovative Approaches in Clinical Trials
    • Basket trials
    • CAR-T cells and BiTE
    • Biomarkers
    • Pharmacogenics


Drug Discovery 2019 will bring together Industry leaders from around the world will join together and discuss the advancements, challenges and successes of discovery and develop new medications and therapies. Don't miss the opportunity to participate in this groundbreaking conference, which is absolutely free to all participants. Enjoy our Leaderboard, where you can move around the entire event, earning points for a chance to win one of LabRoots most popular t-shirts.


Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2018 Drug Discovery Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (PACE) credits. To earn educational credits, you must view an entire presentation. Following the presentation, you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRdrug to follow the conversation!


Speakers

Show Resources
You May Also Like
NOV 02, 2016 06:00 AM PDT
C.E. CREDITS
NOV 02, 2016 06:00 AM PDT
The 7th annual Clinical Diagnostics & Research conference is now On Demand!  This premiere venue discusses the latest advances in clinical diagnostics, research and medicine. The con...
SEP 14, 2016 06:30 AM PDT
C.E. CREDITS
SEP 14, 2016 06:30 AM PDT
An industry leader in delivering instrument systems, reagents, and services to life science researchers,Beckman Coulter Life Sciences helps enable new discoveries in biology-based research...
NOV 08, 2017 06:00 AM PST
C.E. CREDITS
NOV 08, 2017 06:00 AM PST
LabRoots invites you to the 8th annual Clinical Diagnostics & Research free online conference! Clinical diagnostics is an ever-changing field of medicine and research, challenged wit...
NOV 11, 2015 06:00 AM PST
C.E. CREDITS
NOV 11, 2015 06:00 AM PST
Welcome to LabRoots’ 6th Annual Clinical Diagnostics & Research free online conference! The event is now available on-demand and you can attend sessions including keynotes...
FEB 22, 2017 06:00 AM PST
C.E. CREDITS
FEB 22, 2017 06:00 AM PST
Precision Medicine 2017 was a success and is now availabe On Demand!Imagine receiving a full diagnosis from a simple blood test, or the ability to tailor the perfect treatment to your ind...
MAY 28, 2014 06:00 AM PDT
C.E. CREDITS
MAY 28, 2014 06:00 AM PDT
This year will be our 5th annual Clinical Diagnostics & Research online conference. Attendees can earn free CME and CE Credits. The theme of this conference is a range of medical and clin...
Agenda
  • FEB 27, 2019 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Reimagining Drug Discovery and Development Journey Through AI
    Speaker: Szczepan Baran, VMD, MS
  • FEB 27, 2019 07:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Second Harmonic Generation Detection of Ras Conformational Changes and Discovery of a Novel Small-Molecule Binder
    Speaker: Frank McCormick, PhD
  • FEB 27, 2019 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Fully Automated IHC Multiplexing: Techniques and Assay Development
    Speaker: Mark Hellewell, PhD
    Sponsored By: Roche Diagnostics
  • FEB 27, 2019 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance
  • FEB 27, 2019 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    In Vivo Surgical Models for Drug Discovery: Hidden Pitfalls and Their Avoidance
  • FEB 27, 2019 12:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Why Pain Control Is Good Science-The Scientific Rationale
    Speaker: Marcel Perret-Gentil, DVM, MS
  • FEB 27, 2019 01:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Application of Pharmacogenomics During Clinical Trials
  • FEB 27, 2019 01:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Aptamers in Drug Development: From Biomarker Discovery to Targeted Drug Delivery to Small Molecule Drug Detection
    Speaker: Bill Jackson, PhD
  • FEB 27, 2019 03:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    BASKET Trials: Biomarker Driven Drug Development
    Speaker: Shivaani Kummar, MD, FACP
  • FEB 27, 2019 03:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Biomarkers of Aging
    Speaker: Alex Zhavoronkov, PhD
  • Effective Tools for Drug Development
  • FEB 27, 2019 06:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Reimagining Drug Discovery and Development Journey Through AI
    Speaker: Szczepan Baran, VMD, MS
  • FEB 27, 2019 03:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Biomarkers of Aging
    Speaker: Alex Zhavoronkov, PhD
  • Novel Strategies for Drug Discovery
  • FEB 27, 2019 07:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Second Harmonic Generation Detection of Ras Conformational Changes and Discovery of a Novel Small-Molecule Binder
    Speaker: Frank McCormick, PhD
  • FEB 27, 2019 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    In Vivo Surgical Models for Drug Discovery: Hidden Pitfalls and Their Avoidance
  • FEB 27, 2019 12:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Why Pain Control Is Good Science-The Scientific Rationale
    Speaker: Marcel Perret-Gentil, DVM, MS
  • FEB 27, 2019 01:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Aptamers in Drug Development: From Biomarker Discovery to Targeted Drug Delivery to Small Molecule Drug Detection
    Speaker: Bill Jackson, PhD
  • Innovative Approaches in Clinical Trials
  • FEB 27, 2019 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Fully Automated IHC Multiplexing: Techniques and Assay Development
    Speaker: Mark Hellewell, PhD
    Sponsored By: Roche Diagnostics
  • FEB 27, 2019 10:30 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance
  • FEB 27, 2019 01:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Application of Pharmacogenomics During Clinical Trials
  • FEB 27, 2019 03:00 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    BASKET Trials: Biomarker Driven Drug Development
    Speaker: Shivaani Kummar, MD, FACP
Speakers

  • Frank McCormick, PhD
    Professor of the UCSF Helen Diller Family Comprehensive Cancer Center
    Biography
      Frank McCormick, PhD, FRS, is Professor of the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick's group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies. Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.
    • Szczepan Baran, VMD, MS
      Global Head, Animal Welfare and Compliance Training, Novartis Institutes for Biomedical Research
      Biography
        Dr. Szczepan Baran is the Global Head, Animal Welfare and Compliance Training at Novartis Institutes for Biomedical Research. Dr. Baran received a Bachelor of Science in Pre-Veterinary Medicine from the University of Delaware, a Veterinary Medical Doctoral degree from the University of Pennsylvania School of Veterinary Medicine and a Master of Science in Comparative Medicine from the University Of Washington School Of Medicine. In 2005, he joined Fred Hutch Cancer Research Center where he was a member of the team that discovered the first canine embryonic stem cells. Then in 2007 Dr. Baran founded and became COO of the Veterinary Bioscience Institute before his current employment at Novartis. Dr. Baran founded the LinkedIn group "Laboratory Animal Science and Medicine," the largest group in this field. He also served as, Graduate Course Director, Drexel University College of Medicine, Assistant Professor at Delaware Valley, Adjunct Assistant Professor, Department of Pathology, Wake Forest School of Medicine and most notably as Director at Large for the Academy of Surgical Research as well as a Board Member of Americans for Medical Progress. His research interests include use of microfluidics in safety pharmacology and toxicology, the development and validation of online surgical training programs, and the development and validation of rodent endoscopic procedures. Dr. Baran's hobbies include boxing, micro-facial expressions and psychology of adolescent communication.
      • Mark Hellewell, PhD
        DISCOVERY Reagent & Training Lead, Companion Diagnostics (CDx) & DISCOVERY, Roche Tissue Diagnostics
        Biography
          Mr. Hellewell has been with Roche Tissue Diagnostics (RTD) for 8 years where he has held several positions within the company. He began his career with RTD UK where he held sales and applications positions. In 2016 he relocated to Tucson, AZ to take up a global role with customer support for RTD. In 2107 he joined the DISCOVERY International Business team as Global Reagent and Training Lead, where he manages their reagent portfolio and global DISCOVERY training activities for customers and RTD personnel.
        • Christopher Bunker, PhD
          Vice President of Business Development, Advanced Cell Diagnostics
          Biography
            Dr. Christopher Bunker is the Vice President of Business Development at Advanced Cell Diagnostics (ACD) in Newark, California. Dr. Bunker completed his doctoral research in Biological Chemistry at Harvard University and a Leukemia Society of America postdoctoral fellowship in molecular genetics at UCSF. He was a senior scientist in cancer functional genomics at Genome Therapeutics before joining Cell Signaling Technology at its inception in 2000. Dr. Bunker received an M.B.A from Boston University. He joined ACD in 2010, where he has led its assay services business for the past 8 years.
          • Matthew Flegal, BS, SRS
            Senior Associate Scientist, Behavioral Pharmacology and Surgery, Biogen
            Biography
              Matt entered the research field over 24 years ago as a lab animal technician at the TSI/Mason contract research facility. Since then, he has worked at contract facilities such as TSI and OREAD Biosafety as well as in industry at Pharmacia, Pfizer, Sanofi-Aventis, and Biogen. During that period he has performed a variety of surgical procedures including device implantation, transplants, orthopedic defect, ocular and vascular implants, cardiac surgery, and brain and spinal procedures. His experience ranges from mice and rats to non-human primates and livestock. In addition, he holds four patents for novel surgical devices and implants and has been training technicians, scientists, veterinarians, and physicians in surgical techniques and procedures for over 18 years. Outside of the surgical realm, he has been a study director, sonographer, Safety Pharmacology scientist, and manager. Currently Matt supervises a team of associates at Biogen who conduct surgical and non-surgical studies. Matt was also on the board of directors for the Academy of Surgical Research for over ten years, serving as their program chair for three of them as well as educational chair for two. Currently he is the program chairman for the New England branch of AALAS.
            • Annette Gilchrist, PhD
              Associate-Professor, Pharmaceutical Sciences, Midwestern University
              Biography
                An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she co-founded that focused on identifying modulators of G protein-coupled receptors (GPCRs) utilizing novel approaches (US Patent Numbers 6,559,128; 7,208,279; and 7,294,472). Her current research is on allosteric and functionally selective modulators of GPCRs with her primary receptors of interest being the chemokine receptor CCR1 and the recently deorphanized FFAR2. She is an International Editor for the British Journal of Clinical Pharmacology and recently served as a guest co-editor for a Frontiers in Endocrinology Bone Research themed issue on "Chemokines and Bone".
              • Bill Jackson, PhD
                Founder and Chief Scientist, Base Pair Biotechnologies
                Biography
                  Dr. Jackson has served as Principal Investigator on over $5M in Small Business Innovation and Research grants. Dr. Jackson is also a recognized leader in the aptamer space, having authored twelve peer-reviewed publications on aptamers as well as 50+ posters and conference proceedings. In 2010 he co-authored the first market research report on aptamers. Dr. Jackson is inventor on twelve issued U.S. patents (and many corresponding international filings) as well as numerous patents pending. Dr. Jackson holds a B.S. in biomedical engineering and a B.A. in Spanish literature from Texas A&M University and a Ph.D. in chemical engineering from the University of Houston.
                • Jagath Reddy Junutula, PhD
                  Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
                  Biography
                    Over 15 years of experience in oncology drug discovery and development/antibody therapeutics and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Recognized in the scientific and pharmaceutical communities for inventing and developing a novel and innovative THIOMAB technology platform to obtain engineered ADCs with defined number of payloads per conjugate. Authored over 100 patents/peer-reviewed publications and have been a featured keynote speaker at many international high-profile scientific conferences. Led cross-functional teams in the discovery of innovative Antibody Dug Conjugates (ADCs) and Bi-specific cancer immunotherapeutic programs. Core member of launched T-DM1 (Kadcyla) R&D team. Led the teams, which discovered and developed a next generation site-specific T-DM1 ADC project and over 10 other ADC/Bi-specific antibody therapeutic candidates. Leveraged several cross-functional teams in discovery research, pre-clinical research and manufacturing to move antibody based therapeutic molecules from discovery to IND.
                  • Shivaani Kummar, MD, FACP
                    Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford), Director Phase I Clinical Research, Director, Translational Oncology Program, Stanford University
                    Biography
                      Dr. Shivaani Kummar is a medical oncologist who specializes in early phase clinical drug development. She is Professor of Medicine and Director of the Phase I Clinical Research, Medical Oncology, and Translational Oncology Programs at Stanford University. She trained in Internal Medicine at Emory University in Atlanta, Georgia, and then pursued her fellowship training at the National Institutes of Health in Medical Oncology and Hematology. She then became Assistant Professor of Medicine at Yale Cancer Center, Yale University School of Medicine, where she developed in an interest in developmental therapeutics. She moved back to the National Cancer Institute (NCI), NIH, to build a clinical research program in novel cancer therapeutics and in 2011 became Head of Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, NCI. She subsequently moved to Stanford University in 2015 to create their early phase program in medical oncology. Her research interests focus on developing novel therapies for cancer, conducting pharmacokinetic and pharmacodynamic driven first-in-human trials. The clinical studies integrate genomics, imaging, and laboratory correlates into early phase trials. She serves on multiple national and international committees, and has widely published in high impact peer reviewed journals. She also serves as the Associate Division Chief for Medical Oncology.
                    • Marcel Perret-Gentil, DVM, MS
                      University Veterinarian & Director, Laboratory Animal Resources Center, University of Texas at San Antonio
                      Biography
                        Dr. Perret-Gentil currently serves as University Veterinarian and Director of the Laboratory Animal Resources Center at the University of Texas at San Antonio. He is also the Attending Veterinarian of the START Center for Cancer Care in San Antonio and Lester Smith Medical Research Institute. His educational background includes a Bachelor of Science in Animal Science, a Doctorate in Veterinary Medicine, a Residency and Master of Science in Comparative Medicine and a Fellowship in Experimental Minimally Invasive Surgery. Past employment has been with the United States Army, Ethicon Endo-Surgery, Merck, University of Florida and Texas Tech Health Sciences Center. As of the January of 2019, Dr. Perret-Gentil has published or contributed to 60 papers, articles and abstracts. He has presented 388 special presentations at various academic and research institutions, as well as national and international meetings. He serves as ad hoc Specialist for AAALAC International, and as consultant to the government, biotechnology industry and other institutions of higher education in the United States and abroad.
                      • Khyati Shah, PhD
                        Post Doctoral Research Scholar at University of California, San Francisco
                        Biography
                          Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
                        • Martin Shaw
                          Business Development Manager at AroCell AB
                          Biography
                            Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson. From 1975-1992 Martin Shaw filled many technical and marketing roles at Pharmacia Diagnostics (now Thermo-Fisher). He and his coworkers developed and introduced the first commercial tests for neonatal hypothyroidism, celiac disease, and a range of novel biomarkers to monitor allergy and inflammation. Bringing testing close to the patient is important and Martin brings this experience from being Marketing Manager at Magnasense Technologies, Finland, where he introduced and promoted a novel point-of-care test system based on magnetically labelled antibodies. Martin has published several peer-reviewed articles on biomarkers and presented at many scientific congresses, including being guest speaker at the FDA.
                          • Alex Zhavoronkov, PhD
                            Founder and CEO, Insilo Medicine, Inc.
                            Biography
                              Dr. Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He was the first to develop the deep-learned multi-modal predictors of age for drug and biomarker development. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he published over 120 peer-reviewed research papers and books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen's University, a master's in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
                            Sponsored By

                            For information on becoming a sponsor or exhibitor, please click here.


                            C.E. Credits

                            The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                            Committee

                            To download the Program Committee brochure here.


                            • Annette Gilchrist

                              An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she ...

                              See more See less
                            • Khyati Shah, PhD

                              Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                              See more See less
                            • Martin Shaw

                              Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...

                              See more See less
                            • Matthew Flegal, BS, SRS

                              Matt entered the research field over 24 years ago as a lab animal technician at the TSI/Mason contract research facility. Since then, he has worked at contract facilities such as TSI and OREAD Biosafety as well as in industry at Pharmacia, Pfizer, Sanofi-Aventis, and Biogen ...

                              See more See less
                            • Sid Topiol, PhD

                              Sid Topiol is the founder and CSO of 3D-2drug LLC, a collaborative research organization incubating drug discovery projects. 3D-2drug is rooted in the deployment of protein structure/function information into novel and efficient drug discovery opportunities. Sid received his B.S ...

                              See more See less
                            Help

                            General LabRoots Questions

                            For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                            Contact us

                            Virtual Events and Webinars

                            Supported Configurations

                            • Operating System Internet Explorer Firefox Chrome Safari
                              Vista IE8+ FF10+ Chrome15+
                              Windows 7 IE8+ FF10+ Chrome15+
                              Windows 8 IE10 FF10+ Chrome15+
                              Mac OS X   FF10+ Chrome15+ Safari5.1+
                            • Cookie settings: session cookies enabled
                            • Browser configuration must have JavaScript enabled
                            • Adobe Flash player 10.2 or later

                            To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                            Internet Connection

                            • A minimum of 100Kbps is recommended for audio-only events
                            • A minimum of 300Kbps is recommended for speaker on-video events

                            Computer Equipment

                            • Screen Resolution: Minimum 1024x768
                            • Video Card: 65,000 colors minimum
                            • Sound card and speakers (or headphones) for hearing webcast in full format
                            • Audio Card: 16-bit minimum
                            • RAM: 512MB of free RAM

                            Firewall Protocol

                            • HTTP on port 80 or HTTPS on port 443
                            • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                            • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                            Work-At-Home Attendees

                            • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                            For A Seamless Experience

                            When using a mobile device, FREE Mobile Apps are available:

                            - For viewing Webinars:

                            - For viewing Virtual Events

                            Attendee Guide

                            • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                            Virtual Event and Webinar Support:

                            Continuing Education (CME/CE) Support

                            Loading Comments...